CGT · BCMA

92개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved92 programs
CGTLimited DatastaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleDavid WaldPhase 1

UF-KURE-BCMA CAR T-cells (UF-KURE-BCMA CAR T-cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBioray LaboratoriesPhase 1

Universal BCMA-CD19 CART (Universal BCMA-CD19 CART)

Autoimmune Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChengdu Ucello Biotechnology Co…Phase 1

allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA (allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA)

SLE - Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleThe Children's Hospital of Zhej…Phase 1

anti-BCMA/CD70-CAR-T cells (anti-BCMA/CD70-CAR-T cells)

CAR T Cell Therapy; Systemic Lupus Erythematosus · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology & Blood…Preclinical

anti-BCMA/GPRC5D bispecific CAR-T (anti-BCMA/GPRC5D bispecific CAR-T)

Extramedullary Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

anti-CD19 and anti-BCMA CAR (anti-CD19 and anti-BCMA CAR)

Safety and Efficacy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJieyang People's HospitalPhase 1

anti-CD19/BCMA CAR NK cells (anti-CD19/BCMA CAR NK cells)

IgA Nephropathy (IgAN) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastalePeng LiuPhase 1

anti-CD19/BCMA CAR-T cells (anti-CD19/BCMA CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Progression · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19/BCMA U CAR T (anti-CD19/BCMA U CAR T)

Relapsed/Refractory Immune Nephropathy; Relapsed/Refractory Immune-mediated Kidney Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 2

umbilical cord blood CD19-BCMA CAR-T cells infusion (umbilical cord blood CD19-BCMA CAR-T cells infusion)

Refractory Lupus Nephritis; Systemic Sclerosis · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

5 / 5 pages

← PreviousNext →